Sydney, Australia 3 April 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce changes to its senior executive team to help its focus on commercial development and execution of its pipeline of radiopharmaceutical products for the treatment of children and adults with cancer.
Dr Matt Harris, the current Managing Director of Clarity, will move to Chief Scientific Officer and remain on the Board of Directors, and Clarity’s current Chief Operating Officer, Dr Colin Biggin, will move to Acting Chief Executive Officer, whilst an international search, expected to take 6-9 months, for a CEO will begin.
Dr Biggin’s background in radiopharmaceutical development is extensive with over 15 years in the industry, including his experience at Algeta ASA (Algeta) where he worked in multiple roles from 2006 up to Algeta’s acquisition by Bayer for US$2.9 billion in 2014. Dr Biggin was among the first ten employees at Algeta and was responsible for providing scientific and project support across all departments, gaining broad expertise in Regulatory & Quality Assurance, Quality Control, Research and Clinical Development, Manufacturing and Commercial. He was significantly involved in the development and launch of Xofigo, Algeta’s lead radiopharmaceutical product targeting metastatic prostate cancer.
Dr Biggin gained his PhD in Environmental Radiochemistry and a BSc in Environmental Biogeochemistry from the University of Glasgow.
Dr Matt Harris has been integral to the successful development of the company from inception through to its early stage development and will continue his role on the Board of Directors and within the senior executive team as Chief Scientific Officer. These changes at the senior executive level will accommodate Clarity’s focus on moving from an early to a later stage clinical development company. This also coincides with the recent addition of Dr Robert Miller as Contract Chief Medical Officer and Dr Thomas Ramdahl to the Board of Directors, having all gained significant clinical and commercialisation experience through their involvement at Algeta.
Dr Biggin commented on his appointment: “I am looking forward to steering Clarity and the team as Acting CEO through this important stage of development when we are both expanding our clinical program, and preparing for extensive commercial growth of our theranostic platform. I have enjoyed working at Clarity and seeing the Company expand significantly in the last few years and am excited to apply the experience I gained at Algeta to lead Clarity to further success.”
Clarity’s Executive Chairman, Dr Alan Taylor commented “The changes at the executive and Board level will prepare us for transitioning the Company to a new commercial stage of development. We want to bring the right expertise to successfully drive our clinical program and with Dr Thomas Ramdahl joining our Board recently, we are now building a Board and management team with people who have relevant clinical and commercial experience and a track record of successfully growing radiopharmaceutical companies.”
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
